Table 1: Summary of laboratory results from previously reported cases
and current case.
Patient |
Age |
Anti-PD-1 Agent |
Glucose Level at Presentation |
C-peptide Level |
GAD65 antibody positive? |
1 |
54 F |
Pembrolizumab |
N/A |
N/A |
No |
2 |
55 F |
Nivolumab |
532 mg/dL |
< 0.1
ng/mL |
Yes |
3 |
58 M |
Nivolumab |
749 mg/dL |
< 0.1
ng/mL |
Yes |
4 |
63 M |
Nivolumab |
247 mg/dL |
1.3 ng/mL |
Yes |
5 |
64 M |
Pembrolizumab |
703 mg/dL |
0.5 ng/mL |
No |
6* |
77 F |
Nivolumab |
504 mg/dL |
0.81
ng/mL |
No |
7 |
83 F |
Nivolumab |
350 mg/dL |
< 0.1
ng/mL |
Yes |
*Patient 6 represents data obtained from the case reported in
this manuscript.